This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Queen's University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $2,184,076
A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
CIHR · 2022 · Principal investigator
A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Principal investigators: Rushton-Marovac, Moira K; Cescon, David W; Seymour, Lesley
Keywords: Aromatase Inhibitor And Cdk4/6 Inhibitor Resistance; Biomarker; Circulating Tumour Cells (Ctcs); Circulating Tumour Dna (Ctdna); Hormone-Positive Metastatic Breast Cancer; Liquid Biopsy; Platform Trial; Umbrella Trial
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.